Silibinin is a polyphenolic flavonoid isolated from milk thistle with anti-neoplastic activity in several in vitro and in vivo models of cancer, including prostate cancer. Silybin-phytosome is a commercially available formulation containing silibinin. This trial was designed to assess the toxicity of high-dose silybin-phytosome and recommend a phase II dose. Silybin-phytosome was administered orally to prostate cancer patients, giving 2.5-20 g daily, in three divided doses. Each course was 4 weeks in duration. Thirteen patients received a total of 91 courses of silybin-phytosome. Baseline patient characteristics included: median age of 70 years, median baseline prostate specific antigen (PSA) of 4.3 ng/ml, and a median ECOG performance status of 0. The most prominent adverse event was hyperbilirubinemia, with grade 1-2 bilirubin elevations in 9 of the 13 patients. The only grade 3 toxicity observed was elevation of alanine aminotransferase (ALT) in one patient; no grade 4 toxicity was noted. No objective PSA responses were observed. We conclude that 13 g of oral silybin-phytosome daily, in 3 divided doses, appears to be well tolerated in patients with advanced prostate cancer and is the recommended phase II dose. Asymptomatic liver toxicity is the most commonly seen adverse event.
We have examined the role of NAD(P)H:quinone oxidoreductase 1 (NQO1) in the bioreductive metabolism of 17-allylamino-demethoxygeldanamycin (17-AAG). High-performance liquid chromatography (HPLC) analysis of the metabolism of 17-AAG by recombinant human NQO1 revealed the formation of a more polar metabolite 17-AAGH 2 . The formation of 17-AAGH 2 was NQO1 dependent, and its formation could be inhibited by the addition of 5-methoxy-1,2-dimethyl-3-[(4-nitrophenoxy)methyl]indole-4,7-dione (ES936), a mechanismbased (suicide) inhibitor of NQO1. The reduction of 17-AAG to the corresponding hydroquinone 17-AAGH 2 was confirmed by tandem liquid chromatography-mass spectrometry. 17-AAGH 2 was relatively stable and only slowly underwent autooxidation back to 17-AAG over a period of hours. To examine the role of NQO1 in 17-AAG metabolism in cells, we used an isogenic pair of human breast cancer cell lines differing only in NQO1 levels. MDA468 cells lack NQO1 due to a genetic polymorphism, and MDA468/NQ16 cells are a stably transfected clone that express high levels of NQO1 protein. HPLC analysis of 17-AAG metabolism using cell sonicates and intact cells showed that 17-AAGH 2 was formed by MDA468/NQ16 cells, and formation of 17-AAGH 2 could be inhibited by ES936. No 17-AAGH 2 was detected in sonicates or intact MDA468 cells. Following a 4-hour treatment with 17-AAG, the MDA468/NQ16 cells were 12-fold more sensitive to growth inhibition compared with MDA468 cells. More importantly, the increased sensitivity of MDA468/NQ16 cells to 17-AAG could be abolished if the cells were pretreated with ES936. Cellular markers of heat shock protein (Hsp) 90 inhibition, Hsp70 induction, and Raf-1 degradation were measured by immunoblot analysis. Marked Hsp70 induction and Raf-1 degradation was observed in MDA468/NQ16 cells but not in MDA468 cells. Similarly, downstream Raf-1 signaling molecules mitogen-activated protein kinase/extracellular signal-regulated kinase (ERK) kinase and ERK also showed decreased levels of phosphorylation in MDA468/NQ16 cells but not in MDA468 cells. The ability of 17-AAG and 17-AAGH 2 to inhibit purified yeast and human Hsp90 ATPase activity was examined. Maximal 17-AAG-induced ATPase inhibition was observed in the presence of NQO1 and could be abrogated by ES936, showing that 17-AAGH 2 was a more potent Hsp90 inhibitor compared with 17-AAG. Molecular modeling studies also showed that due to increased hydrogen bonding between the hydroquinone and the Hsp90 protein, 17-AAGH 2 was bound more tightly to the ATP-binding site in both yeast and human Hsp90 models. In conclusion, these studies have shown that reduction of 17-AAG by NQO1 generates 17-AAGH 2 , a relatively stable hydroquinone that exhibits superior Hsp90 inhibition. (Cancer Res 2005; 65(21): 10006-15)
Negative ion electrospray ionization, fast-atom bombardment, and low energy tandem mass spectrometry were used for the analysis of dihydroxy-eicosatrienoic acids, which contain a vicinol diol and three nonconjugated double bonds, dihydroxy-eicosatetraenoic acids, which contain a conjugated triene structure, and trihydroxy-eicosatetraenoic acids, which contain a vicinol diol and a conjugated tetraene structure. In general, the product ion spectra were qualitatively similar for both modes of ionization, but electrospray ionization was strikingly more efficient in generation of abundant carboxylate anions that could be collisionally activated to yield product ion spectra. Collision-induced dissociation fragmentation mechanisms were described generally by α-hydroxy fragmentations directed by relative positions of double bonds and were consistent with stable isotope labeling studies. Rearrangement of the conjugated triene system in dihydroxy-eicosatetraenoic acids may be described by formation of a cyclohexadiene structure. Fragmentations that involve a two-proton transfer were described best by intramolecular oxidation of a hydroxy substituent to an enolate that resulted in an extended conjugated system. Collision-induced dissociation spectra obtained for the polyhydroxy unsaturated fatty acids, which are isobaric within each class, were uniquely descriptive of individual structures.
The low-energy collision-induced dissociation (CID) of the carboxylate anions generated by fast atom bombardment ionization of monohydroxy unsaturated fatty acids derived from oleic, linoleic, linolenic and arachidonic acids were studied in a tandem quadrupole mass spectrometer. The collisional activation spectra revealed structurally informative ions as to the position of the hydroxyl substituent in relationship to the sites of unsaturation. Five mechanisms are proposed for the fragmentation of hydroxyl substituted unsaturated fatty acids and are dependent upon the presence of alpha- or beta-unsaturation sites. These mechanisms include charge-remote allylic fragmentation, charge-remote vinylic fragmentation, charge-driven allylic fragmentation, charge-driven vinylic fragmentation, and homolytic fragmentation by an oxy-Cope rearrangement process. The assignment of specific fragmentation pathways was supported in many instances with deuterium-labeled analogs. Although no single fragmentation mechanism appears to predominate, a rational approach to the interpretation of these CID spectra is proposed. The CID spectra of unknown compounds could be used to establish the hydroxyl substituent position in relationship to certain sites of unsaturation but would not be indicative of all double bond locations. The oxy-Cope rearrangement is specific for a structural unit, namely the 3-hydroxy-1,5-diene moiety.
We have previously evaluated the role of NAD(P)H:quinone oxidoreductase 1 (NQO1) in the bioreductive metabolism of 17-(allylamino)-demethoxygeldanamycin (17AAG) to the corresponding hydroquinone, a more potent 90-kDa heat shock protein (Hsp90) inhibitor. Here, we report an extensive study with a series of benzoquinone ansamycins, which includes gel-danamycin, 17-(amino)-17-demethoxygeldanamycin, and 17-demethoxy-17-[[2-(dimethylamino)ethyl]amino]-geldanamycin. The reduction of these benzoquinone ansamycins by recombinant human NQO1 to the corresponding hydroquinone ansamycins was monitored by high-performance liquid chromatography (HPLC) and confirmed by liquid chromatography/ mass spectrometry. Inhibition of purified yeast Hsp90 ATPase activity was augmented in the presence of NQO1 and abrogated by 5-methoxy-1,2-dimethyl-3-[(4-nitrophenoxy)methyl-]indole-4,7-dione (ES936), a mechanism-based inhibitor of NQO1, showing that the hydroquinone ansamycins were more potent Hsp90 inhibitors than their parent quinones. An isogenic pair of human breast cancer cell lines, MDA468 and MDA468/ NQ16, differing in expression of NQO1, was used, and HPLC analysis showed that hydroquinone ansamycins were formed by the MDA468/NQ16 cells, which could be prevented by ES936 pretreatment. The MDA468/NQ16 cells were more sensitive to growth inhibition after treatment with the benzoquinone ansamycins compared with the MDA468 cells; this increased sensitivity could be reduced by ES936 pretreatment. The increased duration of benzoquinone ansamycin exposure showed increased potency and -fold inhibition in MDA468/NQ16 cells relative to the parental MDA468 cells. Computational-based molecular modeling studies displayed additional contacts between yeast Hsp90 and the hydroquinone ansamycins, which translated to greater interaction energies compared with the corresponding benzoquinone ansamycins. In conclusion, these studies show that the reduction of this series of benzoquinone ansamycins by NQO1 generates the corresponding hydroquinone ansamycins, which exhibit enhanced Hsp90 inhibition.The 90-kDa heat shock protein (Hsp90) is a molecular chaperone responsible for the ATP-dependent folding, stability, and function of a number of "client" proteins that are involved in the development and progression of cancer (Maloney and Workman, 2002;Isaacs et al., 2003); these proteins include ErbB2, Raf-1, Cdk4, Met, mutant p53, telomerase hTERT, Hif-1␣, and the estrogen and androgen receptors. The function of Hsp90 has been shown to be dependent on its ability to bind and hydrolyze ATP (Obermann et al., 1998;Panaretou et al., 1998;Pearl and Prodromou, 2001), and competitive inhibition of ATP binding by the natural product geldanamycin (GM), a benzoquinone ansamycin antibiotic isolated from Streptomyces hygroscopicus, leads to the degradation of the client proteins by the ubiquitin-proteosome pathway (Whitesell et al., 1994;Schulte et al., 1995;An et al., 1997), resulting in cell cycle arrest, differentiation, and apoptosis (Hostein et al., 2001;M...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.